Feature | July 19, 2013

Mount Sinai Medical Center First in New York to Offer HeartMate II Pocket Controller

July 19, 2013 — The Mount Sinai Medical Center is the first medical center in New York City to offer the HeartMate II pocket controller, newly approved by the U.S. Food and Drug Administration (FDA), to help its advanced heart failure patients maintain more active lifestyles. This latest-generation controller for the HeartMate II left ventricular assist device (LVAD) is a new small, lightweight, patient-friendly external controller about the size of a smart phone that easily fits in a patient’s front pocket and powers their heart to pump.

“This new HeartMate II controller is a good step forward for our heart failure patients who are awaiting a heart transplant or in need of long-term, permanent support for their survival,” says Sean P. Pinney, M.D., director of the Advanced Heart Failure & Cardiac Transplantation Program at Mount Sinai. “With its smaller size and intuitive safety features, we expect the new controller will enhance the daily lives of our heart failure patients.”

Mount Sinai has one of the largest LVAD programs in the United States, with its cardiothoracic surgeons implanting approximately 50 each year. The center started using LVAD technology in 2006 for advanced heart failure patients. It is used as a bridge-to-transplant (BTT) therapy or destination therapy (DT) for permanent support. In addition, Mount Sinai performs dozens of successful heart transplants each year.

“This new controller will improve the LVAD patient’s overall experience [and] heighten the quality of their life by supporting their active lifestyle, while providing pocket-sized peace of mind for them and their clinical care team,” says Kimberly Ashley, FNP-BC, the VAD program manager for the Advanced Heart Failure & Cardiac Transplantation Program. “We hope to expand the use of this pocket-sized HeartMate II controller to not only new patients but also those current HeartMate II users to give them the option to swap out their old controller for the smaller, safer version, making their lives more comfortable and normal during their daily activities.”

The new patient-friendly controller is a small computer attached to the HeartMate II LVAD via one side cable. It enhances patients’ safety by powering their LVAD to pump their heart, monitoring their vital signs and alerting them of any concerns. Its new design features a diagnostic check system to make sure device wires are intact and functional, special visual alarms, precise onscreen instructions for the patient and longer backup battery power. In addition, the device is programmed with 37 languages to serve diverse patient populations.

“We do extensive patient education training before and after LVAD surgery to teach patients exactly how their controllers work, how to closely monitor their LVAD’s status and also to be vitally aware of any issues or concerns that may arise,” says Bess Griffin, RN, BSN, the VAD coordinator for the Advanced Heart Failure & Cardiac Transplantation Program. “The staff — who have begun training on the new, smart, smaller controller — really enjoy the device’s very easy, user-friendly interface. Thanks to the new controller we are expecting patients may be trained more quickly and feel more confident in caring for their device at home.”

The pocket controller is available for new advanced heart failure patients in need who receive HeartMate II, as well as for current HeartMate II patients who wish to upgrade their existing system controllers.

For more information: www.mountsinai.org

Related Content

Valtech, cardioband, transcatheter mitral annuloplasty

Valtech's Cardioband transcatheter mitral annuloplasty system in development. It is uses a series of corkscrew anchors, similar to those used on EP implantable device leads, to install the annuloplasty ring to reshape the valve for improved leaflet coaptation.

Feature | Structural Heart| September 02, 2015
September 2, 2015 — HeartWare International Inc.
DOPPLER-CIP trial, ESC 2015, heart failure, predictor, small left ventricle, University of Leuven
Feature | Heart Failure| September 02, 2015
Findings presented at the European Society of Cardiology (ESC) Congress 2015 indicate that a small left ventricle with...
Feature | Heart Failure| September 01, 2015
Automated alerts for excess fluid accumulation in the lungs did not improve outcomes for heart failure patients with...
News | Heart Failure| August 28, 2015
August 28, 2015 — BioControl Medical said it has completed enrollment in its INOVATE-HF (INcrease Of VAgal TonE in He
Sunshine Heart, COUNTER HF pivotal study, resumes enrollment, C-Pulse, FDA
News | Heart Failure| August 18, 2015
Sunshine Heart Inc. announced an update in late July on its COUNTER HF U.S. pivotal study for the C-Pulse Heart Assist...
HeartWare, ENDURANCE2 trial, destination therapy, HVAS, HeartWare Ventricular Assist System
News | Ventricular Assist Devices (VAD)| August 11, 2015
HeartWare International Inc. announced that enrollment in the ENDURANCE2 destination therapy clinical trial has been...
Mayo Clinic, LVAD, study, heart failure, restrictive cardiomyopathy, RCM

Thoratec HeartMate II image courtesy of Thoratec

News | Ventricular Assist Devices (VAD)| August 07, 2015
Mayo Clinic is announcing results of a study on the effectiveness of left-ventricular assist devices (LVAD) in treating...
FDA, warning, LVADs, left ventricular assist devices, Thoratec, HeartMate II, HeartWare, HVAD
News | Ventricular Assist Devices (VAD)| August 06, 2015
The U.S. Food and Drug Administration (FDA) is alerting healthcare providers, patients and caregivers about serious...
HeartWare, ventricular assist device, HeartWare VAD, recall, update
News | Ventricular Assist Devices (VAD)| August 05, 2015
HeartWare expanded the Class I recall of its ventricular assist device in mid-June due to concerns over damaged or...
LVADs, heart failure patients, echocardiography, ASE, recommendations, guideline
News | Cardiovascular Ultrasound| August 04, 2015
Over the past several years, advanced heart failure patients who have not responded to medical therapy have been given...
Overlay Init